DK2921486T3 - Sammensætninger og fremgangsmåder til behandling af beta-amyloid-relaterede sygdomme - Google Patents

Sammensætninger og fremgangsmåder til behandling af beta-amyloid-relaterede sygdomme

Info

Publication number
DK2921486T3
DK2921486T3 DK14188202.7T DK14188202T DK2921486T3 DK 2921486 T3 DK2921486 T3 DK 2921486T3 DK 14188202 T DK14188202 T DK 14188202T DK 2921486 T3 DK2921486 T3 DK 2921486T3
Authority
DK
Denmark
Prior art keywords
amyloid
compositions
methods
related diseases
treating beta
Prior art date
Application number
DK14188202.7T
Other languages
English (en)
Inventor
Robert J Ternansky
Amy Allan
Greg Hook
Original Assignee
American Life Science Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Life Science Pharmaceuticals Inc filed Critical American Life Science Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2921486T3 publication Critical patent/DK2921486T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/48Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14188202.7T 2009-08-07 2010-08-06 Sammensætninger og fremgangsmåder til behandling af beta-amyloid-relaterede sygdomme DK2921486T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23238809P 2009-08-07 2009-08-07
US23238309P 2009-08-07 2009-08-07
US29378310P 2010-01-11 2010-01-11
EP10807219.0A EP2462131B1 (en) 2009-08-07 2010-08-06 Compositions and methods for treating beta-amyloid related diseases

Publications (1)

Publication Number Publication Date
DK2921486T3 true DK2921486T3 (da) 2017-11-13

Family

ID=43544958

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14188202.7T DK2921486T3 (da) 2009-08-07 2010-08-06 Sammensætninger og fremgangsmåder til behandling af beta-amyloid-relaterede sygdomme
DK10807219.0T DK2462131T3 (da) 2009-08-07 2010-08-06 Præparater og fremgangsmåder til behandling af beta-amyloid-relaterede sygdomme

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10807219.0T DK2462131T3 (da) 2009-08-07 2010-08-06 Præparater og fremgangsmåder til behandling af beta-amyloid-relaterede sygdomme

Country Status (3)

Country Link
EP (3) EP3296295A1 (da)
DK (2) DK2921486T3 (da)
WO (1) WO2011017600A2 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170166543A1 (en) * 2014-02-03 2017-06-15 American Life Science Pharmaceuticals, Inc. Compositions and methods for synthesizing (2s,3s)-trans-epoxysuccinyl-l-leucyl-amido-3-methylbutane ethyl ester
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
WO2019018445A1 (en) * 2017-07-17 2019-01-24 Maxwell Biosciences, Inc. POLYTHERAPY MODULATING THE MODULATION OF CATHELICIDINE GENE EXPRESSION FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISEASES

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) * 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
WO2002064121A1 (en) 2001-02-13 2002-08-22 Astrazeneca Ab Novel modified released formulation
DE60314495T2 (de) 2002-02-07 2008-03-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aminosäuresequenzen, die in der lage sind die durchdringung einer biologischen barriere zu erleichtern
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
WO2004084830A2 (en) * 2003-03-21 2004-10-07 Buck Institute Method for treating alzheimer’s dementia
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
WO2004112747A2 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8241670B2 (en) 2004-04-15 2012-08-14 Chiasma Inc. Compositions capable of facilitating penetration across a biological barrier
EP1931656B1 (en) 2005-09-28 2011-02-09 Robert Ternansky Novel drugs for dementia
EP2029135A4 (en) 2006-06-13 2011-08-17 Univ Leland Stanford Junior EPOXY HEMMER OF CYSTONE PROTEASES
US20100048717A1 (en) 2006-09-25 2010-02-25 MERCK FROSST CANADA LTD, Merk & Co., Inc. Cathepsin b inhibitors
US7939075B2 (en) 2007-01-11 2011-05-10 Philipps-Universitaet Marburg Human monoclonal anti-amyloid-beta antibodies

Also Published As

Publication number Publication date
EP2921486A1 (en) 2015-09-23
EP3296295A1 (en) 2018-03-21
EP2462131A2 (en) 2012-06-13
EP2462131A4 (en) 2013-01-02
EP2462131B1 (en) 2014-10-15
WO2011017600A2 (en) 2011-02-10
EP2921486B1 (en) 2017-09-27
WO2011017600A3 (en) 2011-06-16
DK2462131T3 (da) 2015-01-05

Similar Documents

Publication Publication Date Title
DK2894165T3 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK2473034T3 (da) Frøbehandlingssammensætninger og fremgangsmåde
DK3128014T3 (da) Midler og fremgangsmåder til sterilisering af biofunktionelle sammensætninger
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK3444342T3 (da) Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
DK2437742T3 (da) Nye sammensætninger til behandling af cmt og beslægtede sygdomme
DK2361090T3 (da) Sammensætninger til behandling af centralt medieret kvalme og opkastning
DK2475372T4 (da) Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse
DK2398902T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer
DK2419732T3 (da) Prionfrie nanopartikelsammensætninger og fremgangsmåder
DK2419670T3 (da) Leveringsmetode og sammensætninger
DK2419114T4 (da) Bakteriesammensætninger til profylakse og behandling af degenerative sygdomme
DK2252342T3 (da) Indretninger og fremgangsmåder til behandling af skadet væv
DK3460056T3 (da) Terapeutiske nukleasesammensætninger og fremgangsmåder
DK2699553T3 (da) Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed
DK2766483T3 (da) Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
DK2473510T3 (da) Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer
DK2504353T4 (da) Lipopeptidsammensætninger og tilsvarende fremgangsmåder
DK2445912T3 (da) Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
DK3284820T3 (da) Fremgangsmåde til behandling af pyropheophytin-holdige sammensætninger
DK3721880T3 (da) Sammensætning og fremgangsmåde til muskelreparation og regenerering
DK2446246T3 (da) Indretning og fremgangsmåde til udvælgelse af partikler
DK2432798T3 (da) 17-hydroxy-17-pentaflourethyl-estra-4,9(10)-dien-11-aryl-derivat, fremgangsmåde til fremstilling heraf og anvendelse heraf til behandling af sygdomme